Engasertib shows promise in hereditary haemorrhagic telangiectasia
In the treatment of patients with hereditary haemorrhagic telangiectasia (HHT), use of the novel allosteric, selective AKT inhibitor engasertib appears to be safe and reduce the frequency and duration of epistaxis, according to a proof-of-concept study.
